泰祥股份(301192.SZ):專注於汽車零部件的研發、製造與銷售
格隆匯7月3日丨泰祥股份(301192.SZ)在投資者互動平台表示,公司專注於汽車零部件的研發、製造與銷售,致力成長為符合國際一流標準的動力及傳動系統核心零部件的全球供應商,大眾汽車集團是現階段公司最主要的客户。公司目前已向國內上汽大眾、大眾一汽(大連)發動機,國外德國大眾汽車、匈牙利奧迪、捷克斯柯達、墨西哥大眾、巴西大眾、印度大眾批量交付產品。作為公司的控股子公司,宏馬科技主要客户包括一汽-大眾、一汽股份、上汽大眾、蒂森克虜伯(ThyssenKrupp)、上海大眾動力總成、大眾一汽發動機、博世華域、華域麥格納、華域皮爾博格泵、捷博軸承、上海黑田(日立指定貿易商)等國際性知名企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.